Chronic Myelomonocytic Leukemia (CMML): A systematic Review of Literature and Update

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI:10.26502/jcsct.5079150

A. Blackmon, I. Amanam, Monzr M. Al Malki, H. Ali, S. Otoukesh

{"title":"Chronic Myelomonocytic Leukemia (CMML): A systematic Review of Literature and Update","authors":"A. Blackmon, I. Amanam, Monzr M. Al Malki, H. Ali, S. Otoukesh","doi":"10.26502/jcsct.5079150","DOIUrl":null,"url":null,"abstract":"Chronic Myelomonocytic Leukemia (CMML) is a hematologic malignancy classified as an overlapping Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) that can transform into Acute Myelogenous Leukemia (AML) with poor outcomes. CMML has distinctive biologic characteristics that may warrant new therapeutic approaches separate from MDS/MPN. There are limited effective therapies for this disease to prevent progression or transformation into AML, and outcomes are often dismal without allogeneic transplantation, especially in patients with high risk disease. As the genomic landscape of CMML continues to unravel and our prognostic scoring systems improve, individualized treatment approaches considering the entirety of this information will follow. We reviewed the literature on the current diagnostic criteria, subtypes of disease, common cytogenetic/molecular J Cancer Sci Clin Ther 2022; 6 (1): 133-145 DOI: 10.26502/jcsct.5079150 Journal of Cancer Science and Clinical Therapeutics 134 aberrations, scoring systems, current treatment and future directions of therapeutic intervention.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer science and clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/jcsct.5079150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic Myelomonocytic Leukemia (CMML) is a hematologic malignancy classified as an overlapping Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) that can transform into Acute Myelogenous Leukemia (AML) with poor outcomes. CMML has distinctive biologic characteristics that may warrant new therapeutic approaches separate from MDS/MPN. There are limited effective therapies for this disease to prevent progression or transformation into AML, and outcomes are often dismal without allogeneic transplantation, especially in patients with high risk disease. As the genomic landscape of CMML continues to unravel and our prognostic scoring systems improve, individualized treatment approaches considering the entirety of this information will follow. We reviewed the literature on the current diagnostic criteria, subtypes of disease, common cytogenetic/molecular J Cancer Sci Clin Ther 2022; 6 (1): 133-145 DOI: 10.26502/jcsct.5079150 Journal of Cancer Science and Clinical Therapeutics 134 aberrations, scoring systems, current treatment and future directions of therapeutic intervention.

查看原文本刊更多论文

慢性髓单细胞白血病(CMML):文献综述和最新进展

慢性髓细胞白血病(CMML)是一种血液系统恶性肿瘤，被归类为骨髓增生异常综合征/骨髓增生性肿瘤(MDS/MPN)重叠，可转化为急性髓系白血病(AML)，预后较差。CMML具有独特的生物学特征，可能需要与MDS/MPN分离的新治疗方法。这种疾病预防进展或转化为AML的有效治疗方法有限，如果没有同种异体移植，特别是在高风险疾病患者中，结果往往令人沮丧。随着CMML的基因组景观继续解开和我们的预后评分系统的改进，考虑到这些信息的整体个性化治疗方法将随之而来。我们回顾了目前的诊断标准，疾病亚型，常见的细胞遗传学/分子[J]癌症科学临床杂志，2022;6 (1): 133-145 DOI: 10.26502/jcsct.5079150癌症科学与临床治疗杂志134失常，评分系统，当前治疗和治疗干预的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of cancer science and clinical therapeutics

自引率

0.00%

发文量